Company news
Krystal Biotech, Inc. news in 2023
Krystal Biotech, Inc.'s news releases, calls and decks from 2023, newest first.
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
December 18, 2023
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
November 26, 2023
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
November 8, 2023
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
November 5, 2023
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
October 29, 2023
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
September 27, 2023
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
September 20, 2023
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 6, 2023
Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
September 4, 2023
Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
August 20, 2023
Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
August 6, 2023
Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707
July 25, 2023
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
July 2, 2023
Krystal Biotech to Present at Upcoming Investor Conferences
June 4, 2023
Krystal Biotech Announces $160 Million Private Placement Equity Financing
May 21, 2023
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
May 18, 2023
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
May 7, 2023
Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program
April 23, 2023
Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest
April 17, 2023
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
April 12, 2023
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
March 5, 2023
Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
March 1, 2023
Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
February 26, 2023
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
January 17, 2023
Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
January 8, 2023
Calls in 2023
Decks in 2023
- Technical Presentation (July 2023)
Technical · 36 slides · Jul 26, 2023